Why It’s the Best Time to Be in Cell and Gene Therapy – Labiotech.eu (blog)
Labiotech.eu (blog) |
Why It’s the Best Time to Be in Cell and Gene Therapy
Labiotech.eu (blog) Cell and gene therapies are here, and they’re here to stay. We stopped to chat about the future of the field with Alexander Vos last week at Bio Europe Spring. The cell and gene therapy space has been given a big boost in the last couple of years … |
Malay Mail |
Stem cell eye treatment safe, restores some vision, study finds
Malay Mail The eye is thought to be a promising site for stem cell transplants, as it is behind a shield called the blood-ocular barrier where there is a weaker immune response. ― AFP picLONDON, March 20 ― Two people with severe vision loss due to a … Nature Cell’s stem cell treatment for Alzheimer’s approved in JapanThe Korea Herald Stem cell eye treatment safe, restores some vision: studyRaw Story Stem Cell Assay: Market Analysis, Strategies, Segmentation and Forecasts, 2018 to 2025Digital Journal Pharmaceuticals News –Business Services –Healthcare Trends all 160 news articles » |
Malay Mail |
Stem cell eye treatment safe, restores some vision, study finds
Malay Mail The eye is thought to be a promising site for stem cell transplants, as it is behind a shield called the blood-ocular barrier where there is a weaker immune response. ― AFP picLONDON, March 20 ― Two people with severe vision loss due to a … Nature Cell’s stem cell treatment for Alzheimer’s approved in JapanThe Korea Herald Stem cell eye treatment safe, restores some vision: studyRaw Story Stem Cell Assay: Market Analysis, Strategies, Segmentation and Forecasts, 2018 to 2025Digital Journal Pharmaceuticals News –Business Services –Healthcare Trends all 160 news articles » |
Harvard School of Engineering and Applied Sciences |
SEAS-developed cancer immunotherapies to be commercialized by …
Harvard School of Engineering and Applied Sciences A Wyss Institute researcher holds a device that can be loaded with immunotherapy agents designed to stimulate the immune system to attack tumor cells. (Image courtesy of the Wyss Institute at Harvard University). Made of the polymer that’s used in … Novartis taps Harvard tech to advance cancer immunotherapy effortsBioPharma Dive Novartis, Harvard, Dana-Farber Partner on Biomaterial for Cancer ImmunotherapiesGenetic Engineering & Biotechnology News Harvard bioengineers’ biomaterial-based cancer immunotherapies to be developed by NovartisPR Newswire (press release) Investing News Network all 12 news articles » |